semaj83/ctmatch_classification huggingface dataset:
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Irritable Bowel Syndrome Healthy volunteers Aged between 18 to 65 years old  Current symptoms or history of gastrointestinal disease, other significant diseases, psychological disorders, drug allergies or pregnancy Taking any medication or have any drug history IBS patients Meet Rome III for IBS. This is defined as recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months associated with two or more of the following: improvement with defecation; onset associated with a change in frequency of stool; or onset associated with a change in form (appearance) of stool Aged between 18 to 65 years old Other significant diseases, psychological disorder, drug allergies or pregnancy Taking any non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids or other immunosuppressive drugs in the preceding 6 months. All drugs potentially affecting gastrointestinal motility or sensitivity will be discontinued at least 1 week before the gastric emptying study
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Nausea Abdominal Pain Chief Complaint of nausea or abdominal pain with nausea Inability to tolerate oral nausea medication Patients with a negative pregnancy test  Patients younger than 18 years of age Patient's chief complaint includes headache, chest pain, or dizziness Patients with whom there are contraindications to using the studied medicine (allergies, known adrenal disease) Blood sugar greater than 300 Non-English speaking subjects
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection One or more episodes recurrent CDI (defined as > 3 loose/watery stools/24h for 2 consecutive days with CDI treatment, and not explained by another diagnosis PLUS laboratory confirmation of C. difficile; or ileus, or toxic megacolon PLUS laboratory confirmation of C. difficile, occurring within 90 days of a prior CDI episode with similar symptoms and laboratory confirmation) 2. Resolution or improvement of symptoms from most recent CDI episode, defined as no longer meeting the clinical definition for CDI for a 48 hour period during treatment, including not meeting the definition again after an initial improvement 3. Within the enrollment window: 2 days after completion of antimicrobial therapy for CDI (to allow for a washout period) to 14 days after completion of therapy or 30 days after the onset of CDI whichever is later. 4. Age 18 years 5. Enrolled in a VHA facility 6. Able and willing to provide informed consent  Unlikely to swallow capsules 2. Pregnancy, planning to be pregnant, or breastfeeding 3. Receipt of cytotoxic chemotherapy, intravenous or subcutaneous immune globulin, or confirmed neutropenia (absolute neutrophil count of < 1,000 cells/ L) within the past 3 months 4. Inflammatory bowel disease or other chronic diarrheal disease/fecal incontinence predating CDI 5. Ongoing antibiotic use other than those for the current episode of CDI 6. Prior FMT 7. Life expectancy of < 8 weeks 8. Anaphylactic food allergy 9. Active enrollment in another research study on antibiotics, probiotics, or FMT without investigators approval 10. Presence of an ileostomy or colostomy 11. HIV with CD4 count < 200 cells/�L in prior 3 months 12. Decompensated cirrhosis 13. Bone marrow/peripheral blood stem cell transplant in the past year 14. Unlikely to follow study protocol
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Pain, Postoperative Opioid Use Adult Scheduled for an elective primary THA with a participating surgeon Planned for Combined Spinal Epidural anesthesia (CSE) and Patient Controlled Epidural Analgesia (PCEA) English-speaking Patients that did not receive pre-operative opioids  Hepatic or renal insufficiency, as defined by abnormal readings on liver and kidney functioning tests Hypersensitivity or contraindication to protocol medication Contraindication for CSE and PCEA Incapable to provide consent/answer questions in English Revision or urgent surgery Receiving Periarticular Injections History of opioid use Patients on disability or worker's compensation
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 20.0-64.0,  Chronic Dizziness Persistent postural-perceptual dizziness (diagnosed by the diagnostic guideline of ICD-11 beta version at Dec. 2016) Existing handicap due to dizziness (DHI equal to or more than 16) Written consent  Vertigo/dizziness/unsteadiness by organic brain diseases, diagnosed by neuro-otologist Vertigo/dizziness/unsteadiness explained by only organic cause or drug, diagnosed by neuro-otologist Physical status inappropriate for psychotherapy or vestibular rehabilitation Current psychiatric disorder other than anxiety disorders, somatic symptom disorder, or illness anxiety disorder (DSM-5), diagnosed by psychiatrist History of schizophrenia or bipolar disorder diagnosed by psychiatrist Increased risk of suicide or self-harm diagnosed by psychiatrist Started or increased SSRI/Venlafaxine within 1 month before treatment Any cognitive behavioral therapy or vestibular rehabilitation except this study Otological surgery or device therapy for dizziness Insufficient understanding of the Japanese language
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Non-arteritic Anterior Ischemic Optic Neuropathy Patients aged 20-65 years. 2. NAION patients who have been diagnosed clinically by a minimum of 1 consultant Division NO with onset ≥6 weeks. 3. Best corrected visual acuity ≥ 1/60 Snellen 4. Patients have to get an explanation about the purpose of the research and all the procedures that will be undertaken and willing to participate in the study by signing the informed consent. 5. On bilateral NAION, examination of research done on one eye at a nearby onset of 6 weeks  Haziness of refractive media, such as corneal opacities and opacities in the lens of moderate to severe (color and turbidity of the lens, the cortex and the posterior capsule with degrees LOCs III> 3). 2. Abnormalities in the macula and the optic disc due to causes other than NAION. 3. Patients with a history of glaucoma. 4. Patients with intraocular inflammation such as anterior and posterior uveitis. 5. Taking antioxidant supplements or other neuroprotective agents in the last 2 weeks before randomization. 6. Edema of optic nerve head condition detected clinically or by OCT
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-88.0,  Intradialytic Hypotension Immersion chronic hemodialysis patients  anemia (HB<10) active infectious disease cognitive impairment dialysis access installed in the leg inability to cooperate with the study procedure Clinically evident overhydrated patients(edema, pulmonary congestion, pulmonary effusion)
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Functional Gastrointestinal Disorders Abdominal Pain Dyspepsia Nausea Vomiting Flatulence Patients with dyspepsia Women and men aged between 18 and 75  Unwilling to consent
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Cerebrospinal Fluid PD diagnosed within the past 5 years Taking a monoamine oxidase (MAO) inhibitor Able to provide consent At least18 years old  Taking levodopa in any form Known allergy to NAC Already taking an anti-oxidant dietary supplement (e.g., Olive Leaf Extract, MitoQ) A condition that would increase risk from a lumbar puncture (e.g., symptomatic spinal stenosis or myoclonus) History of a post-spinal headache that required treatment with a blood patch On a prescribed anti-coagulant (e.g., Coumadin, Plavix) Pregnant or breast-feeding History of alcohol or drug abuse Any medical condition thatcould put subjects at increased risk. Potential participants are excluded who have evidence of bone marrow, liver, or kidney failure based on abnormal screening lab results On a medication that could interfere with the scientific results. An example of an exclusionary drug is the catechol-O-methyltransferase inhibitor entacapone. Tricyclic anti-depressants are another type of exclusionary drug
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Crohn Disease General criterion All of the following Clinical suspicion of CD Age > 15 years Negative serologic markers for celiac disease, negative stool culture (or polymerase chain reaction) for pathogenic bacteria and a negative microscopy for intestinal parasites Fecal calprotectin > 50 mg/kg Signed informed consent Clinical criterion Diarrhea and/or abdominal pain for more than 1 month (or repeated episodes of diarrhea and/or abdominal pain) associated with one or more of the following findings: (1) C-reactive protein (CRP) >5 mg/L, (2) thrombocytosis (> 400 x 109/L), anemia (hemoglobin < 7.0 mmol/L for women and < 8.0 mmol /L for men or a decrease > 0.5 mmol/L compared to the usual level), (3) prolonged fever (> 37.5 C for more than 2 weeks), (5) weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight), (6) perianal abscess/fistula, or (7) a family history of inflammatory bowel disease  Acute bowel obstruction Intake of NSAIDs or acetylsalicylic acid ≤ 4 weeks before except prophylactic treatment with low dose Aspirin (≤ 150 mg per day) Pregnancy or lactation Alcohol or drug abuse Known gastrointestinal disorder other than inflammatory bowel disease Renal failure defined by a plasma-creatinine above the normal reference range Claustrophobia, cardiac pacemaker or implanted magnetic foreign bodies that precludes MREC Interpreter required or inability to understand the oral and written information Colonoscopy contraindicated, performed within 3 months or unwillingness to go through colonoscopy
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hemodialysis Complication Fluid Overload Dialysis Disequilibrium Intra-dialytic Hypotension Hypertension Age >18 years Patients undergoing thrice weekly in-center conventional HD At least 90 days since start of hemodialysis Absence of pulmonary edema / signs of fluid overload on physical exam Currently dialyzing at a DNa >=137 mEq/L Single session Kt/V >=1.3 each month for the past 2 months Hypertensive, defined by a pre-dialysis BP of >140/90 or treatment with 1 or more antihypertensive agents No more than 1 skipped treatment and no more than 1 session per month shortened by >10 min Life expectancy >12 months Able to provide Informed Consent  Prone to IDH, defined as IDH occurring in >10% of treatments in the past 3 months. IDH will be defined as symptoms (e.g. cramps, dizziness, loss of consciousness) and/or intra or post-dialytic systolic BP <90 mm Hg and/or use of intervention(s) (UF goal lowered, treatment stopped early, or saline given) because of IDH Pregnancy
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 3.0-12.0,  Quality of Life Malnutrition Growth Arrest The Randomized Clinical Trial (RCT) will typically involve 250 subjects randomized into two arms based on age and sex. Following a positive outcome in the RCT (following 6 months), we envisage converting the study to an observational based study (case-study) based on ethical principles where the placebo arm of the study would be administered the test product. Each subject will be assessed for a total of two years Inpatient setting: Children with age of 3 years to 12 years with acute diarrhea Outpatient setting: healthy children aged 3 years to 12 years  Subjects taking any kind of prescription medication Subjects taking any dietary supplements (2-week washout is permitted) Subjects taking any antibiotics (must have discontinued antibiotic use 12-weeks prior to beginning study). An allowance will be made to existing subjects already taking part in the study. This confounder will however have to be noted by the primary investigators Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk Including subjects who are bed or wheelchair-bound Including subjects who have any physical disability which could interfere with their ability to perform the functional performance measures included in this protocol
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Biomarkers Diagnosed with gastric cancer (histological or cytological) Attending health centers of the Red UC Christus network for at least 3 months with clinical follow-up. Capable to read and speak spanish Willing and able to provide written informed consent to eh study that should be dated and signed informed consent  With small biopsy samples insufficient for analysis. Whose medical records cannot be collected or are unavaible Without signed informed consent